Eli Lilly Opens 346K-SF R&D Center in Boston Seaport
Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport that occupies 346,000 square feet in a 12-story property developed and operated by Alexandria Real Estate Equities, Inc. The space will include the first East Coast location of Lilly Gateway Labs (LGL), to which Tevard Biosciences will relocate its corporate headquarters.
“The opening of LSC expands upon Lilly’s longstanding presence in the Boston area,” said Daniel Skovronsky, chief scientific officer and president, Lilly Research Laboratories and president, Lilly Immunology. “We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most.”
Cambridge, MA-based Tevard said Tuesday that it was selected to join the LGL community based on its tRNA platform technologies and promising programs for neurological disorders, cardiology, and muscular dystrophies.
